The dipeptidyl peptidase-4 inhibitor sitagliptin improves vascular endothelial function in type 2 diabetes
| Autor: | Masaaki Miyamoto, Gen Takagi, Sonoko Kirinoki-Ichikawa, Yoshiaki Kubota, Kotoko Tanaka, Kyoichi Mizuno, Takeshi Ikeda |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Male
medicine.medical_specialty Vasodilator Agents Vasodilation Type 2 diabetes Dipeptidyl peptidase-4 inhibitor Gastroenterology Drug Administration Schedule Nitroglycerin Internal medicine Medicine Humans Dipeptidyl Peptidase-4 Inhibitor Prospective Studies Endothelial dysfunction Prospective cohort study Aged Aged 80 and over Dipeptidyl-Peptidase IV Inhibitors Adiponectin business.industry Sitagliptin Phosphate Type 2 Diabetes Mellitus General Medicine Middle Aged Triazoles medicine.disease Atherosclerosis Endocrinology Diabetes Mellitus Type 2 Endothelial Function Sitagliptin Pyrazines Endocrinology Nutrition & Metabolism Regression Analysis Female Original Article Endothelium Vascular business medicine.drug |
| Zdroj: | Journal of Korean Medical Science |
| ISSN: | 1598-6357 |
| Popis: | The vascular endothelial function is impaired in the very early stage of atherosclerosis in diabetic patients. The goal of this study was to identify the mechanism underlying the improvement in vascular endothelial function by sitagliptin in type 2 diabetes mellitus patients. This study was an open-labeled prospective observational single arm trial. Forty patients were treated with 50 mg of sitagliptin once daily for 12-weeks. The flow-mediated dilation (FMD) and plasma adiponectin were measured at baseline and 12 weeks after initiating treatment. The %FMD was significantly increased after treatment (4.13 ± 1.59 vs 5.12 ± 1.55, P < 0.001), whereas the nitroglycerin-mediated dilation (NMD) did not change. The plasma adiponectin levels significantly increased (13.0 ± 11.3 vs 14.3 ± 12.8, P < 0.001). The changes in the FMD were significantly correlated with those of the plasma adiponectin (r = 0.322, P < 0.05). A multivariate linear regression analysis demonstrated that the improvement in the FMD is associated with the plasma adiponectin (P < 0.05). The treatment of type 2 diabetes mellitus patients with sitagliptin reverses vascular endothelial dysfunction, as evidenced by increase in the FMD, and improvement of the adiponectin levels (UMIN Clinical Trials Registry System as trial ID UMIN000004236). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|